Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
The concerns raised by Rutter et al. with respect to possible unequal open-label drop-in of glucose-lowering agents were considered in the risk-assessment component of our trial design. Rosiglitazone was not permitted at enrollment in our trial, and its use was discouraged during the trial because...
| Автори: | , |
|---|---|
| Формат: | Journal article |
| Опубліковано: |
Massachusetts Medical Society
2015
|